Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AVTX-803 | Experimental | Approximately 4 subjects will receive AVTX-803 at a dose specified by the investigator up to 5 times a day not to exceed 1700 mg/kg/day for 8 weeks. |
|
| Withdrawal | No Intervention | Subject will be in withdrawal for 8 weeks. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AVTX-803 (L-Fucose) | Drug | L-fucose crystalline powder |
|
| Measure | Description | Time Frame |
|---|---|---|
| Effect of AVTX-803 on the percent of leukocytes expressing Sialyl-Lewis X antigen | To assess the effect of AVTX-803 in subjects with leukocyte adhesion deficiency Type II (LAD II) by evaluating Sialyl-Lewis X on leukocytes as a percentage present at the end of each 8 week treatment period. | Change from Baseline at Day 56, Change from Baseline at Day 112 |
Not provided
Not provided
Inclusion Criteria:
Subject must be between 6 months and 75 years old
Subject has biochemically and genetically proven LAD II (SLC35C1-CDG)
Subject has a documented history of Lewis antigen deficiency
Subject has a history of recurrent infections, opportunistic infections or infections that did not respond well to standard of care treatment
Subject or parent (for subjects under legal age for consent) has provided written informed consent for this study. Additionally, written informed assent has been provided, as appropriate, for minors of older age, per local institutional review board (IRB)/ethics committee (EC) policy and requirements
Subject is willing and able to comply with the protocol
Women of childbearing potential (WOCBP) meeting the criteria below:
Male subjects must agree to use an acceptable double-barrier method of contraception with their partner as determined by the investigator or sub-investigator for the duration of the study and 30 days following the last dose of study drug.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jennifer Lin | Contact | 3052833827 | huiyil@augtx.com |
| Name | Affiliation | Role |
|---|---|---|
| David Deyle, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic | Recruiting | Rochester | Minnesota | 55905 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C535887 | Leukocyte adhesion deficiency type 1 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005643 | Fucose |
| ID | Term |
|---|---|
| D003837 | Deoxy Sugars |
| D002241 | Carbohydrates |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided